Basilea Takes On Partner J&J In Arbitration Claim Over Ceftobiprole Delays

In an era where most product- and innovation-hungry big pharma firms have been desperately promoting themselves as "best partners," it is perhaps easy to forget what can go wrong when a biotech entrusts its asset to a larger firm